Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy
Status:
Completed
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
1. Evaluate quantitative VCEUS imaging for determining early breast cancer response to
neoadjuvant chemotherapy and compare results to co-temporal volume change on grayscale
ultrasound and post-treatment mammography findings utilizing final surgical pathology
and clinical outcome.
2. Assess incremental benefit of quantitative VCEUS to planar CEUS tumor perfusion
measurements and enhancement patterns in predicting tumor response to adjuvant
treatment in clinical studies.
The contrast agent Definity® is FDA approved for use as a contrast agent during ultrasound
(echocardiography) of the heart. Definity® will be used "off-label" (during ultrasound of
the breast) in this study. The administration of Definity® during this study will follow
total dose guidelines approved by the FDA.